Status:
UNKNOWN
Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy
Lead Sponsor:
N.N. Blokhin National Medical Research Center of Oncology
Conditions:
Non Small Cell Lung Cancer
T790M
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to assess safety of Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression during or after therapy with a prior EG...
Detailed Description
This study is a multicenter non-interventional retro- and prospective study of safety and efficacy of the Osimertinib administration in frames of Early Access Program (EAP) and real clinical practice ...
Eligibility Criteria
Inclusion
- Participation in Osimertinib EAP and /or taking / completion therapy with Osimertinib in real clinical practice;
- Confirmed diagnosis of IIIB (locally advanced) or IV (metastatic) stages of NSCLC with T790M EGFRm;
- Progression of the disease that occurred during or after the therapy with first- or second-generation EGFR TKI
Exclusion
- Participation in any other clinical study;
- Absence of data essential for obtaining all necessary information in full.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05314296
Start Date
June 1 2020
End Date
December 1 2022
Last Update
April 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federal State Budgetary Institution National Medical Research Center of Oncology named after N.N. N.N. Blokhin" of the Ministry of Health of Russia
Moscow, Russia, 115478